Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Caladrius Biosciences, Inc. CLBS
$0.43
На 13:46, 16 марта 2023
Ранг: 3
Ключевые показатели
-
Marketcap
3351368.00000000
-
week52high
-
week52low
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.91330400
-
EPS
-0.39400000
-
Last Dividend
0.56000000
-
Next Earnings Date
02 ноя 2022 г. в 04:00
Описание компании
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 23 мар 2022 г. |
| Brookline Capital | Buy | Buy | 03 мар 2021 г. |
| WBB Securities | Speculative Buy | 14 мая 2019 г. | |
| Chardan Capital | Buy | Buy | 23 мар 2018 г. |
| H.C. Wainwright | Buy | Buy | 07 мар 2018 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| AZAB MOHAMMAD | A | 19200 | 19200 | 15 сент 2022 г. |
| Mazzo David J | D | 739444 | 69742 | 01 сент 2022 г. |
| Mazzo David J | A | 809186 | 150000 | 01 сент 2022 г. |
| Buck Kristen K | D | 307244 | 44776 | 01 сент 2022 г. |
| Buck Kristen K | D | 352020 | 25183 | 01 сент 2022 г. |
| Buck Kristen K | A | 377203 | 58000 | 01 сент 2022 г. |
| Mazzo David J | D | 631065 | 6611 | 14 янв 2022 г. |
| Girolamo Todd C | D | 160827 | 2158 | 14 янв 2022 г. |
| Mazzo David J | D | 637676 | 6471 | 13 янв 2022 г. |
| Girolamo Todd C | D | 162985 | 2563 | 13 янв 2022 г. |
Новостная лента
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
04 авг 2022 г. в 22:59
Caladrius Biosciences, Inc. (NASDAQ:CLBS ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, CEO Kristen Buck - EVP, Research and Development & CMO James Nisco - VP, Finance & Treasury Conference Call Participants Kumar Raja - Brookline Capital Pete Enderlin - MAZ Partners Operator Welcome to the Caladrius Biosciences' Second Quarter 2022 Financial Results and Business Update Conference Call. Currently all participants are in listen-only mode.
Caladrius Biosciences to Present at the BIO International Convention 2022
GlobeNewsWire
08 июн 2022 г. в 08:00
BASKING RIDGE, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the BIO International Convention being held in-person at the San Diego Convention Center in San Diego, CA, from June 13-16, 2022.
Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference
GlobeNewsWire
18 мая 2022 г. в 08:00
BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the H.C. Wainwright Global Investment Conference being held both virtually and in-person at the Fontainebleau Miami Beach Hotel in Miami, FL on May 23-26, 2022.
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2022 Results - Earnings Call Transcript
Seeking Alpha
05 мая 2022 г. в 23:29
Caladrius Biosciences, Inc. (NASDAQ:CLBS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants John Menditto - VP, Investor Relations & Corporate Communications David Mazzo - President & Chief Executive Officer James Nisco - Vice President of Finance & Treasury Kristen Buck - Chief Medical Officer Conference Call Participants Kumar Raja - Brookline Capital Markets Pete Enderlin - MAZ Partners Operator Welcome to the Caladrius Biosciences First Quarter 2022 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode.
Caladrius Biosciences To Merge With Privately-Held Cend Therapeutics
Benzinga
27 апр 2022 г. в 12:25
Caladrius Biosciences Inc (NASDAQ: CLBS) and privately-held Cend Therapeutics Inc have agreed to merge in an all-stock approximate "merger of equals" transaction approved by the Boards of Directors of each company. The transaction values each company at $90.